Researchers at the University of California, Irvine, have found that some antibody-drug conjugates, an emerging class of targeted cancer therapies, were associated with serious infection-related complications, including hospitalization and intensive care admissions. The study analyzed treatment data from 3,511 patients…
Pharmacy
The 340B Drug Pricing Program is under pressure from multiple directions: pharmacy benefit manager litigation, drugmaker contract pharmacy restrictions, and a federal rebate pilot that courts have effectively killed. For health systems, the program represents one of the most significant…
Rockford, Ill.-based Mercyhealth has opened a new pharmacy in Beloit, Wis., expanding access to prescription services for patients in the community, according to a June 2 report from WIFR. Mercyhealth Pharmacy-Beloit is one of 11 pharmacies operated by the health…
The FDA has issued a complete response letter for Cingulate’s new drug application seeking approval of CTx-1301 for the treatment of attention-deficit/hyperactivity disorder. The agency’s response identified specific Chemistry, Manufacturing and Controls information requests and did not raise any current…
Madison, Wis.-based UW Health has expanded its prescription delivery service, offering free next-day home delivery for patients in Dane County, Wis. The health system has provided home prescription delivery since 2012, but deliveries previously took several days through carriers such…
Advertisement
At a time when healthcare executives are being asked to stretch scarce federal resources as far as possible, the 340B Drug Pricing Program is a much-appreciated lifeline. Despite the program being around for over three decades, the need for its…
Eli Lilly has given some 340B hospitals five business days to begin submitting claims-level data or risk losing access to discounted drug pricing, escalating a growing dispute over transparency requirements in the federal drug discount program. In a June 1…
About $300 billion in revenue generated by rated pharmaceutical companies is expected to face generic and biosimilar competition through 2031 — a shift with direct implications for how hospitals and health systems manage their drug budgets over the next several…
An experimental oral cancer drug has shown signs of effectiveness across six types of solid tumors in patients whose cancers had stopped responding to immunotherapy. The therapy, GRWD5769, was evaluated in combination with cemiplimab in patients with secondary anti-PD-1 resistance…
The FDA has approved Xocova (ensitrelvir) for post-exposure prophylaxis of COVID-19 in adults and adolescents age 12 and older following contact with an individual who has COVID-19. The approval makes Xocova the first and only oral option to help prevent…